| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17, 2022 | ESPR Esperion Therapeutics, Inc. | Koenig Sheldon L.60 | President And CEO | Sell | 571 | $4.58 | $2,615.18 | -0.3% | +4.5% | -69.6% | |
| Mar 17, 2022 | ANIP Ani Pharmaceuticals Inc | Shanmugam Muthusamy59 | Head Of R&D, Coo-novitium Ops | Buy | 10,000 | $27.65 | $276,503.00 | +74.3% | -16.1% | +38.9% | |
| Mar 17, 2022 | JNJ Johnson & Johnson | Mongon Thibaut | Exec VP, Ww Chair, Consumer | Sell | 10,874 | $176.26 | $1,916,670.97 | -0.5% | -3.2% | -12.1% | |
| Mar 17, 2022 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 6,000 | $182.42 | $1,094,501.22 | -3.8% | +19.3% | +19.1% | |
| Mar 17, 2022 | LLY Eli Lilly & Co | Jonsson Patrik | SVP&Pres, Lly Imm, Lly Usa&CCO | Sell | 673 | $277.20 | $186,555.60 | -2.1% | +3.0% | +16.4% | |
| Mar 17, 2022 | HIMS Hims & Hers Health, Inc. | O'Keefe Lynne Chou | Director | Sell | 10,044 | $4.50 | $45,198.00 | -100% | -17.8% | +96.8% | |
| Mar 16, 2022 | AMPH Amphastar Pharmaceuticals, Inc. | Peters William J52 | CFO, EVP &Treasurer | Sell | 50,777 | $33.96 | $1,724,427.37 | -18.0% | -9.4% | +9.9% | |
| Mar 16, 2022 | AMPH Amphastar Pharmaceuticals, Inc. | Zasloff Michael A53 | Director | Sell | 10,000 | $33.71 | $337,069.00 | -17.5% | -9.4% | +9.9% | |
| Mar 16, 2022 | BMY Bristol Myers Squibb Co | Vessey Rupert53 | EVP, Research &Early Dev. | Sell | 74,559 | $69.25 | $5,162,972.81 | -43.5% | +5.4% | -1.5% | |
| Mar 16, 2022 | ZTS Zoetis Inc. | Trawicki Roman48 | Executive Vice President | Sell | 6,000 | $188.15 | $1,128,900.00 | -42.2% | -17.6% | -12.8% | |
| Mar 15, 2022 | VTRS Viatris Inc | Cornwell W Don | Director | Buy | 2,700 | $9.90 | $26,721.36 | +14.0% | +9.2% | -1.4% | |
| Mar 15, 2022 | AMPH Amphastar Pharmaceuticals, Inc. | Prins Richard K61 | Director | Sell | 10,000 | $34.02 | $340,208.00 | -18.1% | -14.2% | +6.0% | |
| Mar 15, 2022 | AMPH Amphastar Pharmaceuticals, Inc. | Peters William J52 | CFO, EVP &Treasurer | Sell | 7,900 | $34.46 | $272,248.22 | -7.4% | -14.2% | +6.0% | |
| Mar 15, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 220,075 | $274.96 | $60,511,869.47 | - | +6.1% | +20.7% | |
| Mar 15, 2022 | JNJ Johnson & Johnson | Decker Robert J56 | Controller, CAO | Sell | 5,000 | $175.51 | $877,530.00 | -8.5% | -2.4% | -10.6% | |
| Mar 15, 2022 | BHC Bausch Health Companies Inc. | Spurr Robert82 | U.s. President-pharma Business | Sell | 4,846 | $22.20 | $107,581.20 | -5.0% | -65.5% | -65.3% | |
| Mar 15, 2022 | VTRS Viatris Inc | Goettler Michael | Chief Executive Officer | Buy | 50,352 | $9.87 | $496,772.83 | +58.2% | +9.2% | -1.4% | |
| Mar 14, 2022 | BMY Bristol Myers Squibb Co | Santiago Karen Murphy | SVP &Controller | Sell | 6,577 | $69.20 | $455,095.51 | -28.3% | +7.1% | -1.9% | |
| Mar 14, 2022 | TAK Takeda Pharmaceutical Co Ltd | Takeda Pharmaceutical Co Ltd70 | 10% Owner | Sell | 18 | $19.00 | $342.00 | - | -6.9% | +13.7% | |
| Mar 14, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 173,085 | $269.39 | $46,626,914.97 | - | +8.6% | +22.7% | |
| Mar 14, 2022 | ANIK Anika Therapeutics, Inc. | Colleran David | EVP, General Counsel, Corp Sec | Buy | 1,500 | $26.65 | $39,978.00 | +21.8% | -19.6% | +5.7% | |
| Mar 14, 2022 | BMY Bristol Myers Squibb Co | Boerner Christopher S.60 | EVP, Chief Commercial Officer | Sell | 29,532 | $69.20 | $2,043,525.80 | -41.3% | +7.1% | -1.9% | |
| Mar 14, 2022 | PRGO Perrigo Co Plc | Farrington Thomas | EVP And CIO | Sell | 26,744 | $37.14 | $993,181.88 | -100% | +0.1% | -2.2% | |
| Mar 14, 2022 | IRWD Ironwood Pharmaceuticals Inc | McHugh Julie53 | Director | Sell | 20,000 | $11.67 | $233,400.00 | -14.5% | +0.2% | -7.9% | |
| Mar 11, 2022 | ANIK Anika Therapeutics, Inc. | Levitz Michael L | EVP, CFO, Treasurer | Buy | 4,000 | $24.62 | $98,476.00 | +33.5% | -14.2% | +2.0% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.